Combination therapy with chemotherapy and VDAs

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A growing body of preclinical and clinical evidence substantiates the feasibility of combining vascular disrupting agents (VDAs) and conventional anticancer therapies. The enhanced disease response to this combination is attributable to the respective activity of VDAs on the tumor vasculature and of the cytotoxic drug on proliferating tumor cells. However, the nature of the mode of action of VDAs is likely to cause pathophysiological modifications in the tumor microenvironment that can influence the delivery and the activity of the drug with which is combined. A full understanding of the action of VDAs, together with the pharmacological interactions with cytotoxic drugs, will expedite approaches aiming to maximize the antitumor effects of combination therapy. This review focuses on the rationales underpinning the combination of small molecule VDAs with chemotherapy, discussing the pathophysiological changes associated with VDA activity and implication of these for combination modalities.

Original languageEnglish
Title of host publicationVascular Disruptive Agents for the Treatment of Cancer
PublisherSpringer New York
Pages77-93
Number of pages17
ISBN (Print)9781441966087
DOIs
Publication statusPublished - 2010

Fingerprint

Chemotherapy
Blood Vessels
Drug Therapy
Tumors
Pharmaceutical Preparations
Therapeutics
Tumor Microenvironment
Antineoplastic Agents
Cells
Neoplasms
Molecules
Pharmacology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Taraboletti, G., Bonezzi, K., & Giavazzi, R. (2010). Combination therapy with chemotherapy and VDAs. In Vascular Disruptive Agents for the Treatment of Cancer (pp. 77-93). Springer New York. https://doi.org/10.1007/978-1-4419-6609-4_4

Combination therapy with chemotherapy and VDAs. / Taraboletti, Giulia; Bonezzi, Katiuscia; Giavazzi, Raffaella.

Vascular Disruptive Agents for the Treatment of Cancer. Springer New York, 2010. p. 77-93.

Research output: Chapter in Book/Report/Conference proceedingChapter

Taraboletti, G, Bonezzi, K & Giavazzi, R 2010, Combination therapy with chemotherapy and VDAs. in Vascular Disruptive Agents for the Treatment of Cancer. Springer New York, pp. 77-93. https://doi.org/10.1007/978-1-4419-6609-4_4
Taraboletti G, Bonezzi K, Giavazzi R. Combination therapy with chemotherapy and VDAs. In Vascular Disruptive Agents for the Treatment of Cancer. Springer New York. 2010. p. 77-93 https://doi.org/10.1007/978-1-4419-6609-4_4
Taraboletti, Giulia ; Bonezzi, Katiuscia ; Giavazzi, Raffaella. / Combination therapy with chemotherapy and VDAs. Vascular Disruptive Agents for the Treatment of Cancer. Springer New York, 2010. pp. 77-93
@inbook{9de7e28d58154a4f827398bda15f8604,
title = "Combination therapy with chemotherapy and VDAs",
abstract = "A growing body of preclinical and clinical evidence substantiates the feasibility of combining vascular disrupting agents (VDAs) and conventional anticancer therapies. The enhanced disease response to this combination is attributable to the respective activity of VDAs on the tumor vasculature and of the cytotoxic drug on proliferating tumor cells. However, the nature of the mode of action of VDAs is likely to cause pathophysiological modifications in the tumor microenvironment that can influence the delivery and the activity of the drug with which is combined. A full understanding of the action of VDAs, together with the pharmacological interactions with cytotoxic drugs, will expedite approaches aiming to maximize the antitumor effects of combination therapy. This review focuses on the rationales underpinning the combination of small molecule VDAs with chemotherapy, discussing the pathophysiological changes associated with VDA activity and implication of these for combination modalities.",
author = "Giulia Taraboletti and Katiuscia Bonezzi and Raffaella Giavazzi",
year = "2010",
doi = "10.1007/978-1-4419-6609-4_4",
language = "English",
isbn = "9781441966087",
pages = "77--93",
booktitle = "Vascular Disruptive Agents for the Treatment of Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Combination therapy with chemotherapy and VDAs

AU - Taraboletti, Giulia

AU - Bonezzi, Katiuscia

AU - Giavazzi, Raffaella

PY - 2010

Y1 - 2010

N2 - A growing body of preclinical and clinical evidence substantiates the feasibility of combining vascular disrupting agents (VDAs) and conventional anticancer therapies. The enhanced disease response to this combination is attributable to the respective activity of VDAs on the tumor vasculature and of the cytotoxic drug on proliferating tumor cells. However, the nature of the mode of action of VDAs is likely to cause pathophysiological modifications in the tumor microenvironment that can influence the delivery and the activity of the drug with which is combined. A full understanding of the action of VDAs, together with the pharmacological interactions with cytotoxic drugs, will expedite approaches aiming to maximize the antitumor effects of combination therapy. This review focuses on the rationales underpinning the combination of small molecule VDAs with chemotherapy, discussing the pathophysiological changes associated with VDA activity and implication of these for combination modalities.

AB - A growing body of preclinical and clinical evidence substantiates the feasibility of combining vascular disrupting agents (VDAs) and conventional anticancer therapies. The enhanced disease response to this combination is attributable to the respective activity of VDAs on the tumor vasculature and of the cytotoxic drug on proliferating tumor cells. However, the nature of the mode of action of VDAs is likely to cause pathophysiological modifications in the tumor microenvironment that can influence the delivery and the activity of the drug with which is combined. A full understanding of the action of VDAs, together with the pharmacological interactions with cytotoxic drugs, will expedite approaches aiming to maximize the antitumor effects of combination therapy. This review focuses on the rationales underpinning the combination of small molecule VDAs with chemotherapy, discussing the pathophysiological changes associated with VDA activity and implication of these for combination modalities.

UR - http://www.scopus.com/inward/record.url?scp=84871437164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871437164&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-6609-4_4

DO - 10.1007/978-1-4419-6609-4_4

M3 - Chapter

AN - SCOPUS:84871437164

SN - 9781441966087

SP - 77

EP - 93

BT - Vascular Disruptive Agents for the Treatment of Cancer

PB - Springer New York

ER -